机构：[1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Thoracic Oncology, Fudan University, Shanghai, China[4]Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[5]Department of Thoracic Oncology, The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China[6]Department of Radiation Oncology, Peking University Third Hospital, Beijing, China[7]Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China[8]Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China[9]Department of Radiation Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China[10]Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China[11]Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China[12]Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China[13]Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China河南省肿瘤医院[14]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China[15]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[16]Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, China[17]Department of Radiation and Medical Oncology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China[18]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[19]Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[20]Department of Radiation Oncology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China[21]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China[22]Department of Radiation Oncology, The fourth hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[23]Department of Radiation Oncology, Xijing Hospital, Xi’an, China[24]Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China[25]Department of Radiation Oncology, Korea University Ansan Hospital, Ansan, Republic of Korea[26]Department of Radiation Oncology, Catalan Institute of Oncology, L’Hospitalet, Barcelona, Spain[27]Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands[28]Department of Human Structure and Repair Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium[29]Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA[30]New York Proton Center, New York, USA[31]Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland[32]Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA[33]Department of Radiotherapy, Military Institute of Medicine, Warsaw, Poland[34]Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany[35]Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA[36]Department of Radiation Oncology, Institut Jules Bordet, Université Libre Bruxelles, Brussels, Belgium[37]Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland[38]Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan[39]Department of Radiation Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea[40]Radiotherapy Department, Strasbourg Europe Cancer Institute (ICANS), Strasbourg, France[41]Departments of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan[42]Department of Radiation Oncology, Mayo Clinic, Rochester, MN,USA[43]Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA[44]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Background: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable advances in its technology and the continuous development of cutting-edge therapeutic agents, such as targeted therapy and immune checkpoint inhibitors (ICIs), are increasing its role in the multi-disciplinary management of the disease.Methods: International radiotherapy experts were convened to consider and reach consensuses on the clinical utilities of radiotherapy in metastatic NSCLC, with the aim to provide patient-focused, up to date, evidence-based, recommendations to assist cancer specialists in the management of patients with metastatic NSCLC worldwide.Results: Timely radiotherapy can offer rapid symptom alleviation and allow subsequent aggressive treatment approaches in patients with heavy tumor burden and/or oncologic emergencies. In addition, appropriate incorporation of radiotherapy as concurrent, consolidation, or salvage therapy makes it possible to achieve long-term survival, or even cure, for patients with oligo-metastatic disease. Cranial radiotherapy plays an important role in the management of brain metastasis, potentially augmenting the response and prolonging survival associated with targeted agents and ICIs. However, key questions remain, such as the appropriate choice of radiation techniques, optimal sequence of systemic therapies and radiotherapy, and optimal patient selection for such combination strategies. Although a strong rationale for combining radiotherapy and ICIs exists, its optimal parameters in this setting remain to be established.Conclusions: In the modern era, radiotherapy serves not only as a palliative tool in metastatic NSCLC, but also plays active roles in patients with oligo-focal disease, CNS metastasis and receiving ICIs.
基金：
Science and Technology Commission of Shanghai Municipality [20Y11913500, 19411965900]; Hospital Development Center of Shanghai [SHDC2020CR4010]
第一作者机构：[1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Thoracic Oncology, Fudan University, Shanghai, China[*1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[3]Institute of Thoracic Oncology, Fudan University, Shanghai, China[4]Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[5]Department of Thoracic Oncology, The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China[43]Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA[44]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China[*1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China.[*2]Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA[*3]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China[*4]Department of Thoracic Oncology, The Affiliated Hospital of Guizhou Medical University and The Affiliated Cancer Hospital of Guizhou Medical University, No. 1 Beijing Road West, Guiyang 550004, China.[*5]Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huai-Hai Road, Shanghai 200030, China
推荐引用方式(GB/T 7714)：
Zhengfei Zhu,Jianjiao Ni,Xuwei Cai,et al.International consensus on radiotherapy in metastatic non-small cell lung cancer[J].TRANSLATIONAL LUNG CANCER RESEARCH.2022,doi:10.21037/tlcr-22-644.
APA：
Zhengfei Zhu,Jianjiao Ni,Xuwei Cai,Shengfa Su,Hongqing Zhuang...&Xiaolong Fu.(2022).International consensus on radiotherapy in metastatic non-small cell lung cancer.TRANSLATIONAL LUNG CANCER RESEARCH,,
MLA：
Zhengfei Zhu,et al."International consensus on radiotherapy in metastatic non-small cell lung cancer".TRANSLATIONAL LUNG CANCER RESEARCH .(2022)
